Edwards Lifesciences (EW) Gross Margin (2009 - 2026)

Edwards Lifesciences has reported Gross Margin for 18 years, with the latest figure at 77.46% in Q2 2026.

• On a quarterly basis, Gross Margin fell 6.0% year-over-year to 77.46% in Q2 2026; TTM through Jun 2026 was 77.84%, a 103.0% decrease from a year earlier, with the FY2025 full-year figure at 78.01%, down 144.0% from the prior year.
• Gross Margin was 77.46% for Q2 2026 at Edwards Lifesciences, down from 78.01% in the prior quarter.
• The five-year high for Gross Margin was 122.98% in Q4 2022, with the low at 77.46% in Q2 2026.
• Average Gross Margin over 5 years is 81.62%, with a median of 79.38% recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 4626 bps in 2022, then slumped 4280 bps in 2023.
• Over 5 years, Gross Margin stood at 122.98% in 2022, then sank by 35 bps to 80.18% in 2023, then retreated by 2 bps to 78.91% in 2024, then decreased by 1 bps to 78.15% in 2025, then declined by 1 bps to 77.46% in 2026.
• The last three Gross Margin figures came in at 77.46% (Q2 2026), 78.01% (Q1 2026), and 78.15% (Q4 2025), per Business Quant data.